The Brand Name ARIXTRA Has Generic Salt :: FONDAPARINUX 

ARIXTRA  Is From Company Gsk Priced :: Rs. 690

ARIXTRA have FONDAPARINUX is comes under Sub class #N/A of  Main Class #N/A

Main Medicine Class:: #N/A  Sub Medicine Class :: #N/A 

 Salt Name :  OR Generic Name Form Price : MRP /Probable Packing
FONDAPARINUX  INJ  Rs. 690  0.5ML
Brand Name Company / Manufacturers Strength Unit Price / 0.5ML
 ARIXTRA  Gsk  2.5MG/0.5ML  0.5ML Rs. 690

Company  Brand Name  Salt Combination Main Medical Class Sub Medical Class
 From Gsk :: ARIXTRA  FONDAPARINUX  #N/A #N/A

Indications for Drugs ::

Venous thromboembolic events, acute DVT, pulmonary embolism (PE), unstable angina or non-ST segment elevation MI

Drug Dose ::

Adult Prevention of VTE in orthopedic & abdominal surgery 2.5 mg SC once daily, starting not <6 hr post-op & after hemostasis is established for at least 5-9 days, up to an additional 24 days in hip fracture. Patients at risk of thromboembolic complications 2.5 mg SC once daily for 6-14 days. DVT & PE >100 kg body wt 10 mg, 50-100 kg body wt 7.5 mg, <50 kg body wt 5 mg. Doses to be administered SC once daily for at least 5 days & until adequate oral anticoagulant is established (INR 2-3). Initiate concomitant treatment w/ vit K antagonists w/in 72 hr. Duration: 5-9 days. UA/NSTEMI 2.5 mg SC once daily for up to 8 days or until hospital discharge. STEMI 2.5 mg once daily, 1st dose to be given IV & subsequent doses given SC for up to 8 days or until hospital discharge. Renal impairment: CrCl (ml/min) 20-50 1.5 mg once daily. <20 Contra-indicated. Contraindication ::

Hypersensitivity. Active clinically significant bleeding, acute bacterial endocarditis.

Drug Precautions ::

Do not administer IM. Do not give 24 hr prior to CABG surgery & may be restarted 48 hr post-op. STEMI patients undergoing primary PCI for reperfusion. Monotherapy in UA/NSTEMI & STEMI patients undergoing non-primary PCI. Increased risk of hemorrhage eg congenital or acquired bleeding disorders, active ulcerative GI disease, recent intracranial hemorrhage, shortly after brain, spinal or ophth surgery. Low body wt <50 kg; spinal/epidural anesth or spinal puncture. History of heparin-induced thrombocytopenia & latex allergy. Renal (CrCl <20 or 30 mL/min) or severe hepatic impairment. Close monitoring is recommended in patients concomitantly taking products enhancing the risk of hemorrhage. Pregnancy & lactation. Childn <17 yr. Elderly >75 yr.

Drug Side Effects ::

Anemia, bleeding, purpura; edema.

Pregnancy category ::
Pregnancy category

2

Drug Mode of Action ::  

Fondaparinux, a synthetic pentasaccharide, acts as a selective inhibitor of activated factor X. It works by binding selectively to ATIII, and potentiates the neutralisation of Factor Xa. This will interrupt the blood coagulation cascade and inhibit both thrombin formation and thrombus development. At the recommended dosage, fondaparinux does not affect fibrinolytic activity or platelet function. It cannot lyse established thrombi and does not affect clotting function tests (e.g. aPPT, INR).

Drug Interactions ::

Increased risk of bleeding w/ (e.g. desirudin, fibrinolytic drugs, glycoprotein IIb/IIIa-receptor antagonists, heparin, heparinoids or LMWH).

 

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.

We would like to keep you updated with special notifications.